UA66783C2 - Antigestagenic steroids - Google Patents

Antigestagenic steroids

Info

Publication number
UA66783C2
UA66783C2 UA99094999A UA99094999A UA66783C2 UA 66783 C2 UA66783 C2 UA 66783C2 UA 99094999 A UA99094999 A UA 99094999A UA 99094999 A UA99094999 A UA 99094999A UA 66783 C2 UA66783 C2 UA 66783C2
Authority
UA
Ukraine
Prior art keywords
stands
group
hydrogen atom
steroids
hydrogen
Prior art date
Application number
UA99094999A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UA66783C2 publication Critical patent/UA66783C2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UA99094999A 1997-02-07 1998-02-09 Antigestagenic steroids UA66783C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19706061A DE19706061A1 (de) 1997-02-07 1997-02-07 Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
PCT/EP1998/000752 WO1998034947A1 (de) 1997-02-07 1998-02-09 ANTIGESTAGEN WIRKSAME STEROIDE MIT FLUORIERTER 17α-ALKYLKETTE

Publications (1)

Publication Number Publication Date
UA66783C2 true UA66783C2 (en) 2004-06-15

Family

ID=7820508

Family Applications (1)

Application Number Title Priority Date Filing Date
UA99094999A UA66783C2 (en) 1997-02-07 1998-02-09 Antigestagenic steroids

Country Status (35)

Country Link
US (4) US6316432B1 (xx)
EP (1) EP0970103B1 (xx)
JP (1) JP4324249B2 (xx)
KR (1) KR100511815B1 (xx)
CN (2) CN1246865A (xx)
AR (1) AR010887A1 (xx)
AT (1) ATE216397T1 (xx)
AU (1) AU742834B2 (xx)
BG (1) BG63875B1 (xx)
BR (1) BR9807667A (xx)
CA (1) CA2280041C (xx)
CL (1) CL2004001191A1 (xx)
CZ (1) CZ296328B6 (xx)
DE (2) DE19706061A1 (xx)
DK (1) DK0970103T3 (xx)
EA (1) EA003092B1 (xx)
EE (1) EE03831B1 (xx)
ES (1) ES2175673T3 (xx)
HK (1) HK1040718B (xx)
HU (1) HUP0000968A3 (xx)
ID (1) ID22643A (xx)
IL (1) IL131226A (xx)
IS (1) IS2190B (xx)
MY (1) MY118508A (xx)
NO (1) NO313554B1 (xx)
NZ (1) NZ336989A (xx)
PL (1) PL191808B1 (xx)
PT (1) PT970103E (xx)
SI (1) SI0970103T1 (xx)
SK (1) SK283155B6 (xx)
TR (1) TR199901855T2 (xx)
TW (1) TW499434B (xx)
UA (1) UA66783C2 (xx)
WO (1) WO1998034947A1 (xx)
ZA (1) ZA98985B (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE10049736A1 (de) * 2000-09-29 2002-04-18 Jenapharm Gmbh 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE10051609A1 (de) * 2000-10-18 2002-05-02 Schering Ag Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
CN1512886A (zh) * 2000-10-18 2004-07-14 ���ֹɷݹ�˾ 抗孕激素预防和治疗激素依赖性疾病的用途
UY26965A1 (es) * 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
UY26966A1 (es) * 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la inducción de apoptosis en una célula
EE200300157A (et) * 2000-10-18 2003-08-15 Schering Aktiengesellschaft Antiprogestiinide kasutamine apoptoosi esilekutsumiseks rakus
DE60123138T2 (de) * 2000-10-18 2007-09-13 Bayer Schering Pharma Ag Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
PL361689A1 (en) * 2001-01-09 2004-10-04 Schering Aktiengesellschaft The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
US20030013694A1 (en) * 2001-05-25 2003-01-16 Jens Hoffmann Use and compositions of antiprogestins for treatment of prostate diseases
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
DE10221034A1 (de) 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
EP1501859B1 (de) * 2002-05-03 2005-10-26 Schering AG 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
BRPI0412219B8 (pt) 2003-07-23 2021-07-27 Bayer Healthcare Llc compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos
US7593347B2 (en) * 2003-12-29 2009-09-22 Intel Corporation Method and apparatus to exchange channel information
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
HUE051484T2 (hu) 2006-10-24 2021-03-01 Allergan Pharmaceuticals Int Ltd Készítmények és eljárások az endometriális proliferációk elnyomására
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
EP2136796A2 (en) * 2007-04-23 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
WO2011119194A1 (en) 2010-03-22 2011-09-29 Repros Therapeutics Inc. Compositions and methods for non-toxic delivery of antiprogestins
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ES2708351T3 (es) 2013-04-11 2019-04-09 Bayer Pharma AG Forma de dosificación de un antagonista del receptor de progesterona
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
US9603856B2 (en) 2013-11-03 2017-03-28 Flamina Holding Ag Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
EP2868321A1 (en) * 2013-11-03 2015-05-06 Flamina Holding AG A composition or group of compositions for inhibiting autocrine HCG production in adult human cells
CA2986064A1 (en) 2015-05-18 2016-11-24 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulator (sprm) regimen
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE310541C (xx) * 1915-12-19 1919-01-30
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2639045B2 (fr) 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
US5064821A (en) * 1982-11-18 1991-11-12 Trustees Of Tufts College Method and compositions for overcoming tetracycline resistance within living cells
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en) * 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
DE3723788A1 (de) * 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
JP2785023B2 (ja) * 1987-12-30 1998-08-13 ルセル―ユクラフ １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
JPH02188599A (ja) * 1988-11-16 1990-07-24 Roussel Uclaf ３―ケト―デルタ―４，９―１９―ノルステロイドから誘導される新物質及びそれらよりなる薬剤
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
CN1055929C (zh) * 1993-09-20 2000-08-30 中国科学院上海有机化学研究所 三氟甲基甾体化合物及其制备方法
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Also Published As

Publication number Publication date
CZ296328B6 (cs) 2006-02-15
IS5147A (is) 1999-08-04
NO993811L (no) 1999-10-04
CA2280041C (en) 2007-10-23
SI0970103T1 (en) 2002-10-31
ZA98985B (en) 1999-08-03
CA2280041A1 (en) 1998-08-13
US6806263B2 (en) 2004-10-19
US20050080060A1 (en) 2005-04-14
AR010887A1 (es) 2000-07-12
ATE216397T1 (de) 2002-05-15
AU6100598A (en) 1998-08-26
BR9807667A (pt) 2000-02-15
EE03831B1 (et) 2002-08-15
DE59803856D1 (de) 2002-05-23
JP2001510479A (ja) 2001-07-31
ES2175673T3 (es) 2002-11-16
CL2004001191A1 (es) 2005-03-28
IL131226A (en) 2004-12-15
US20020045774A1 (en) 2002-04-18
NO993811D0 (no) 1999-08-06
NZ336989A (en) 2001-04-27
HK1040718B (zh) 2005-12-09
DK0970103T3 (da) 2002-07-22
EE9900339A (et) 2000-02-15
EP0970103A1 (de) 2000-01-12
KR100511815B1 (ko) 2005-09-05
MY118508A (en) 2004-11-30
US7148213B2 (en) 2006-12-12
WO1998034947A1 (de) 1998-08-13
AU742834B2 (en) 2002-01-10
PL334878A1 (en) 2000-03-27
HUP0000968A3 (en) 2001-03-28
PT970103E (pt) 2002-09-30
TW499434B (en) 2002-08-21
PL191808B1 (pl) 2006-07-31
BG103603A (en) 2000-06-30
EA199900644A1 (ru) 2000-04-24
BG63875B1 (bg) 2003-04-30
CN1246865A (zh) 2000-03-08
SK283155B6 (sk) 2003-03-04
CN1324802A (zh) 2001-12-05
HUP0000968A2 (hu) 2000-10-28
NO313554B1 (no) 2002-10-21
CZ280599A3 (cs) 2000-01-12
US6503895B2 (en) 2003-01-07
ID22643A (id) 1999-12-02
JP4324249B2 (ja) 2009-09-02
US20030134834A1 (en) 2003-07-17
CN1202120C (zh) 2005-05-18
US6316432B1 (en) 2001-11-13
DE19706061A1 (de) 1998-08-13
SK103899A3 (en) 2000-05-16
TR199901855T2 (xx) 2000-04-21
EP0970103B1 (de) 2002-04-17
IS2190B (is) 2007-01-15
KR20000070835A (ko) 2000-11-25
IL131226A0 (en) 2001-01-28
HK1040718A1 (en) 2002-06-21
EA003092B1 (ru) 2002-12-26

Similar Documents

Publication Publication Date Title
UA66783C2 (en) Antigestagenic steroids
FI972099A (fi) Rikki-substituoidut atsetidinoniyhdisteet, jotka ovat hyödyllisiä hypokolesteroeemisinä aineina
TW427974B (en) Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
HUP0003274A2 (hu) Fenil-metil-benzokinon-származékok, és ezeket a vegyületeket tartalmazó NF-kB inhibitor hatású gyógyszerkészítmények
PT1071702E (pt) Derivados de acidos gordos de acidos biliares e derivados de acidos biliares
IL105078A (en) Pharmaceutical compositions containing 17-(3-pyridyl)- substituted steroids and some new compounds of this type
TR199900293T2 (xx) Alzheimer hastal��� tedavisi i�in bir farmas�tik bile�im �retmek �zere �elat maddesi clioquil'un kullan�m�.
HK1052684A1 (en) Inhibitors of alpha 4 mediated cell adhesion.
GEP20012530B (en) Neuroactive Steroids of the Androstane and Pregnane Series
HUP0104841A2 (hu) Hatóanyagként NF-kB gátló hatású benzokinonszármazékot vagy kondenzált pirimidinszármazékot tartalmazó gyógyszerkészítmények szívizomgyulladás, dilatatív kardiomiopátia vagy szívelégtelenség kezelésére
AU2732597A (en) Novel pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
HUP0202595A2 (hu) A 11-es helyzetben szénhidrogéncsoportot hordozó nem aromás ösztrogén szteroidok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CA2258177A1 (en) 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
BG102661A (en) Benzo/o/quinolysine derivatives, their preparation and application as 5a-reductase inhibitors
EP0972766A4 (en) HYDROQUINONE DERIVATIVES
HUP0003693A2 (hu) Oxidációs bázisként pirazolo[1,5-a]pirimidint és kapcsolóként naftalint tartalmazó festékkészítmény és festési eljárás ennek alkalmazásával
TW333536B (en) 14-17-C2-bridged steroids
AU5125798A (en) Novel n-benzenesulphonyl-l-proline derivatives, method for preparing and therapeutic use
HUP0200913A2 (hu) Izoindoloindolonszármazékok eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
WO2003013420A3 (en) Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification
IL117497A0 (en) 17-Difluoromethylene estratriene derivatives and pharmaceutical compositions containing the same
AU3266089A (en) New triene derivatives having a chromene structure, processes for preparing them and pharmaceutical compositions containing them
ES2009553A6 (es) Procedimiento de preparacion de nuevos derivados del acido 2-(2,3-dihidrido-2-oxo-3-benzofuranil)-acetico.
TH35006A (th) สเทอรอยด์ที่ว่องไวในการต่อต้านเจสทาเจนที่มีโซ่ฟลูออริเนเทค 17 อัลฟา-แอลคิล
HUP0402139A2 (hu) Hormon hatású 17 alfa-hidroxi-14 béta-szteroidok és alkalmazásuk gyógyszerkészítmények előállítására